Intralesional photodynamic therapy induces apoptosis in basal cell carcinoma and Bowen's disease through caspase 3 and granzyme B

J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1311-1317. doi: 10.1111/jdv.19050. Epub 2023 Mar 23.

Abstract

Background: Photodynamic therapy (PDT) is used to treat cutaneous cancers. It may induce cell death through direct and indirect means, including apoptosis, inflammation and certain immune mechanisms, with the depth of penetration as a potential modifying factor.

Objectives: To examine the pathways of apoptosis in the intralesional PDT of basal cell carcinoma (BCC) and intraepidermal squamous cell carcinoma (Bowen's disease).

Methods: Sixteen patients with superficial or nodular BCC and Bowen's disease were treated with intralesional aminolevulinic acid-PDT. Biopsies were taken at baseline and 24 h post-PDT, and sections were examined by immunohistochemistry for the expression of markers of apoptosis, such as caspase 3, involved in the intrinsic apoptotic pathway, granzyme B, a caspase-independent apoptotic mediator, and the proapoptotic markers BAX and BAK.

Results: Apoptotic cells stained with TUNEL showed statistically significant staining at 24 h post PDT (p < 0.01 in both BCC and Bowen's lesions). Caspase 3 (p < 0.01 in BCC and p < 0.05 in Bowen's) and granzyme B (p < 0.01 in BCC and p < 0.01 in Bowen's) were significantly increased at 24 h post-PDT. BAX expression was apparently increased compared to baseline in Bowen's lesions at 24 h post-PDT, whereas Bak was upregulated both in BCC and Bowen's disease at baseline and at 24 h post-PDT.

Conclusion: Intralesional PDT induces apoptosis in BCC and Bowen's disease via common and alternative apoptotic pathways involving granzyme B. Proapoptotic factors Bak in both BCC and Bowen and Bax in Bowen's disease appear to increase by intralesional PDT at 24 h.

MeSH terms

  • Aminolevulinic Acid / therapeutic use
  • Apoptosis
  • Bowen's Disease* / drug therapy
  • Carcinoma, Basal Cell* / drug therapy
  • Caspase 3 / therapeutic use
  • Granzymes / therapeutic use
  • Humans
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use
  • Skin Neoplasms* / drug therapy
  • bcl-2-Associated X Protein / therapeutic use

Substances

  • Photosensitizing Agents
  • Caspase 3
  • Granzymes
  • bcl-2-Associated X Protein
  • Aminolevulinic Acid